ASCO, ACCC invite 75 research sites in the U.S. participate in pilot project of site self-assessment tool, implicit bias training program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Society of Clinical Oncology and the Association of Community Cancer Centers have invited 75 research sites to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.  

Originally planned as a pilot project involving approximately 40-50 research sites, the program has expanded in response to interest from the oncology community. 

The launch of this next phase of the oncology organizations’ collaboration will help ensure racial and ethnic diversity among clinical trial participants and support for clinicians so they are able to routinely offer clinical trials to all eligible patients.

The invited sites represent a diverse mix of small and large research sites at community- and academic-based oncology programs, which will allow ASCO and ACCC to draw actionable conclusions about effectiveness of the tool and training in a variety of research and clinical settings. 

Each site has been assigned to participate in the site self-assessment tool pilot study, the implicit bias training program pilot study, or both pilot studies.

The site self-assessment tool is intended to help research sites conduct an internal assessment of their policies, procedures, and programs that may impact which patients are screened for and offered a clinical trial, as well as factors impacting subsequent enrollment and retention. 

Once the sites enter their responses, they will receive recommendations for specific strategies to implement and improve their performance. After completing their assessments, participants will provide feedback and suggested revisions to enhance the tool.

The implicit bias training program is designed to help research sites acknowledge and mitigate implicit bias across research and care teams related to which patients are offered clinical trials and which choose to participate. It is a virtual, curriculum-based program and includes self-directed and interventional components. Participants’ feedback will be used to enhance the training program.

ASCO and ACCC will work with each of the invited sites to confirm and facilitate participation in the pilot project, which will officially begin this summer.

This work is part of an ASCO-ACCC initiative to establish evidence-based practical strategies and solutions to advance a vision where every patient with cancer has the opportunity to participate in research, focusing initially on patients who are Black and/or Hispanic/Latinx. The collaboration launched in July 2020 with a RFI to the oncology community seeking novel innovations to remedy participation barriers. 

If the tool and training prove useful across a variety of research sites, the organizations plan to explore a longitudinal intervention study to evaluate their effectiveness in diversifying participation of people from all racial and ethnic minority populations historically underrepresented in cancer treatment trials.

Table of Contents

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login